Compare JSPR & JFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JSPR | JFU |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | China |
| Employees | 64 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7M | 37.4M |
| IPO Year | N/A | 2018 |
| Metric | JSPR | JFU |
|---|---|---|
| Price | $0.66 | $2.90 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 371.6K | 6.1K |
| Earning Date | 05-11-2026 | 12-09-2022 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.69 | $1.01 |
| 52 Week High | $7.19 | $9.48 |
| Indicator | JSPR | JFU |
|---|---|---|
| Relative Strength Index (RSI) | 16.03 | 35.33 |
| Support Level | N/A | $2.43 |
| Resistance Level | $1.44 | $2.93 |
| Average True Range (ATR) | 0.09 | 0.42 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 1.60 | 0.00 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.